Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

[1]  S. Förderreuther,et al.  S1-Leitlinie: Therapie der Migräneattacke und Prophylaxe der Migräne , 2023, DGNeurologie.

[2]  M. Filippi,et al.  Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients , 2022, The Journal of Headache and Pain.

[3]  H. Diener,et al.  Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe , 2022, Der Nervenarzt.

[4]  T. Dresler,et al.  [Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]. , 2022, Der Nervenarzt.

[5]  T. Hariyanto,et al.  Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: A systematic review and meta‐analysis , 2022, Clinical and experimental pharmacology & physiology.

[6]  S. Sacco,et al.  European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update , 2022, The Journal of Headache and Pain.

[7]  J. Mehnert,et al.  Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study , 2022, eLife.

[8]  R. Ayyagari,et al.  Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine , 2022, The Journal of Headache and Pain.

[9]  R. Ruscheweyh,et al.  Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study , 2021, Cephalalgia : an international journal of headache.

[10]  C. Kleinschnitz,et al.  CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience , 2021, The Journal of Headache and Pain.

[11]  MD Gil-Sierra,et al.  Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series , 2021, European journal of hospital pharmacy : science and practice.

[12]  J. Sánchez-Rubio Ferrández,et al.  Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series , 2021, European Neurology.

[13]  U. Reuter,et al.  Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis , 2021, CNS Drugs.

[14]  H. Ulmer,et al.  CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis , 2021, Cephalalgia : an international journal of headache.

[15]  T. Taura,et al.  Migraine therapeutics differentially modulate the CGRP pathway , 2021, Cephalalgia : an international journal of headache.

[16]  D. Friedman,et al.  Galcanezumab for the prevention of migraine. , 2020, Pain management.

[17]  J. Haan.  Faculty Opinions recommendation of Central effects of erenumab in migraine patients: An event-related functional imaging study. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[18]  A. May,et al.  Non‐Responders to Treatment With Antibodies to the CGRP‐Receptor May Profit From a Switch of Antibody Class , 2019, Headache.

[19]  Rongsheng Tong,et al.  Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials , 2019, Psychoneuroendocrinology.

[20]  H. Diener,et al.  Therapie der Migräneattacke und Prophylaxe der Migräne , 2018, Nervenheilkunde.

[21]  S. Silberstein,et al.  Fremanezumab for the Preventive Treatment of Chronic Migraine , 2017, The New England journal of medicine.

[22]  U. Reuter,et al.  Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies , 2017, Current opinion in neurology.

[23]  L. Edvinsson.  The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine , 2017, Headache.

[24]  Min Yang,et al.  Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine , 2011, Cephalalgia : an international journal of headache.

[25]  R. Lipton,et al.  Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers , 2000, Pain.

[26]  P. Goadsby,et al.  The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats , 1993, Annals of neurology.

[27]  L. Swanson,et al.  Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing , 1983, Nature.

[28]  M. Arnold.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.

[29]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..